Global Brain Cancer Market Assessment, By Drug [Carmustine, Cisplatin, Bevacizumab, Temozolomide, Belzutifan, Others], By Therapy [Chemotherapy, Targeted Therapy, Immunotherapy, Others], By Indication [Pituitary, Glioma, Meningioma, Others], By End-user [Hospitals, Cancer Centers, Diagnostic Laboratories], By Distribution Channel [Hospital Pharmacy, Retail Pharmacy, Online Pharmacy], By Region, Opportunities and Forecast, 2017-2031F
Global brain cancer market is expected to experience significant growth over the forecast period owing to increasing strategic collaborations between major market players, rising research and development activities, and growing prevalence of brain tumors.
Home>Industry Reports>Global Brain Cancer Market Assessment, Opportunities and Forecast, 2017-2031F
Global brain cancer market is projected to witness a CAGR of 10.03% during the forecast period 2024-2031, growing from USD 2.51 billion in 2023 to USD 5.39 billion in 2031F. The increasing prevalence of the disease in various regions across the globe is expected to boost the growth of the market.
As per the estimates of the American Cancer Society, approximately 25,400 malignant tumors of the spinal cord or brain have been diagnosed in the United States in 2023. Out of these diagnosed cases, 10,980 are expected to be diagnosed in females and 14,420 are expected to be diagnosed in males. It is estimated that roughly 18,760 people will die from spinal cord and brain tumors. The rising awareness about neurological diseases in both children and adults is providing lucrative growth opportunities to the market. The different risk factors that are attributed to an increased chance of developing brain tumors include exposure to viruses, allergens, infections, N-nitroso compounds, and head injuries and seizures.
Increasing efforts of various governments to combat the disease are supporting important research discoveries. Various governments are investing in researching new ways to treat, diagnose, and prevent brain cancer. For instance, the government of Canada is dedicated to the development of new treatment strategies by promoting scientific collaborations. The collaborations with organizations such as the Brain Tumor Foundation of Canada and the Brain Canada Foundation (BC) are aiding in maximizing the impact of research investments. A neurosurgeon-scientist at the University of Toronto and the University Health Network, with the help of brain cancer research funding was able to find new therapies for preventing high-risk surgical procedures and transform the clinical management of patients with brain tumors. Another partnership with the Canadian Cancer Society has united 10 research teams that aim at making life-changing breakthroughs in brain cancer.
Growing Research and Development Activities
The various research activities aimed at spinal cord and brain tumors are dedicated to reducing the different toxic effects associated with effective therapies, identifying the underlying cause of cancer, and determining novel treatments and delivery methods. For instance, in 2023, a team of researchers from the University of Texas at Dallas and UT Southwestern Medical Center developed a method to deliver medication through the blood-brain barrier, using gold nanoparticles. The technique showed positive results for the treatment of glioblastoma, a common form of brain cancer, in the clinical study. The drug delivery method relies on the co-delivery of medication with vessel-targeted gold nanoparticles, that are then injected into the bloodstream. In the experiment, paclitaxel was used by the researchers to conclude the chemotherapy drug for treating lung, ovarian, and breast cancers.
Increasing Prevalence of Disease in Both Children and Adults
According to the American Cancer Society, spinal cord and brain tumors are the second most common type of cancer in children. They account for approximately one out of four cases of cancer in children. Almost three out of four children diagnosed with brain tumors survive at least five years after receiving the diagnosis. Hence, various studies are being conducted to determine the effects of cancer-treating drugs on children, which is further leading to the brain cancer market growth.
For instance, the PIRATE study conducted by EpicentRx, Inc. aims to determine the side effects of RRx-001 in young adults and children when given together with temozolomide and irinotecan. The study aims to determine if the given combination is helpful for young adults and children with previously treated cancerous tumors.
North America is Expected to Account for Significant Market Share
North America is expected to dominate the market due to the growing prevalence of brain cancer in the United States and Canada and the increase in the emphasis on cancer research. According to the National Brain Tumor Society, approximately one million individuals are living with a brain tumor in America and 94,390 individuals are expected to receive a primary brain tumor diagnosis in 2023. The Canadian Cancer Society estimated that, in 2023, 3,200 Canadians will be diagnosed with spinal cord and brain cancer and nearly 2,500 Canadians will die amongst them. Due to the unique challenges presented by brain cancer, research and development activities are increasingly being conducted by various research institutions and market players. Currently, a study is being conducted by the University of Alabama in Birmingham to determine the safety and tolerability of novel gamma-delta T cell therapy for treating patients who recently received a diagnosis of glioblastoma.
Increasing Cases of Glioma Support Market Growth
According to the National Brain Tumor Society, glioblastoma accounts for 50.1% of all primary malignant brain tumors, and has more than 14,490 Americans, expected to receive a diagnosis of glioblastoma in 2023. According to an article published by researchers from MU School of Medicine and the University of Rochester, in May 2023, 6 out of every 100,000 people receive a diagnosis of glioma in the United States every year. Due to the increasing prevalence of glioma in different regions across the globe, research and development activities are increasing to find novel treatment solutions.
Various regulatory bodies such as the Food and Drug Administration (FDA) are providing fast-track designation to drugs that treat glioma. For instance, the FDA granted fast-track designation to the herpes simplex virus-1 (HSV-1) viral immunotherapy agent CAN-3110 as a treatment for enhancing the overall survival of patients suffering from recurrent high-grade glioma. Across all dosing levels, the findings supported the safety of CAN-3110 despite the presence of HSV1 ICP34.5 gene. CAN-3110 is a first in class oncolytic viral immunotherapy that is designed for targeting cancer cells expressing Nestin.
Hospital Pharmacies Expected to Witness Significant Growth
The longstanding trust associated with hospital pharmacies is bolstering the expansion of the segment. Drugs that are essential for treatment of brain tumor are prescribed after the receipt of diagnosis and often require hospital administration. Furthermore, the easy claim of health insurance policies across hospital pharmacies further encourages patients to purchase brain cancer-treating drugs from them. The convenience offered by hospital pharmacies coupled with the assurance of availability of quality products that are within the expiry period is further boosting the segment growth.
On the contrary, online pharmacies are anticipated to witness significant expansion over the forecast period. It is due to the availability of a wide range of benefits offered by online pharmacies including fast delivery and shipping, privacy, and discount codes and coupons. The increasing practice of purchasing medicines from legitimate and verified online pharmacies across developed countries is supporting the expansion of the segment.
Future Market Scenario (2024 – 2031F)
- Increasing research and development activities and supportive government initiatives are expected to support the growth of the market over the forecast period.
- In 2023, a research team at Brigham and Women’s Hospital tested and developed a novel approach for assessing the working of antitumor drugs for different patients. The scientists developed drug releasing microdevices that were used for testing several drugs, however only one of them was administered to the patients. Conducting further studies will aid in determining the effectiveness of microdevices in personalized cancer treatments.
- Several studies are underway to determine the effects of various drugs on both adults and children.
- A study being conducted by the University of Alabama at Birmingham is expected to determine the safety and tolerability of novel gamma-delta T cell therapy for treating patients who recently received a diagnosis of glioblastoma, projected to conclude by December 2024.
Report Scope
“Brain Cancer Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global brain cancer market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031F. Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.
|
Report Attribute |
Details |
|
Base Year of the Analysis |
2023 |
|
Historical Period |
2017-2022 |
|
Forecast Period |
2024-2031F |
|
Projected Growth Rate |
CAGR of 10.03% between 2024-2031F |
|
Revenue Forecast in 2031 |
USD 5.39 billion |
|
Segments Covered |
Drug, Therapy, Indication, End-user, Distribution Channel |
|
Regions Covered |
North America, Europe, South America, Asia-Pacific, Middle East and Africa |
|
Key Companies Profiled |
Pfizer, Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, Johnson & Johnson Inc., Dr. Reddy's Laboratories Ltd., Amgen Inc., EpicentRx, Inc., Siemens Healthineer |
|
Customization Scope |
15% free report customization with purchase |
|
Pricing and Purchase Options |
Avail the customized purchase options to fulfil your precise research needs |
|
Delivery Format |
PDF and Excel through email (subject to the license purchased) |
In this report, global brain cancer market has been segmented into the following categories:
· By Drug
o Carmustine
o Cisplatin
o Bevacizumab
o Temozolomide
o Belzutifan
o Others
· By Therapy
o Chemotherapy
o Targeted Therapy
o Immunotherapy
o Others
· By Indication
o Pituitary
o Glioma
o Meningioma
o Others
· By End-user
o Hospitals
o Cancer Centers
o Diagnostic Laboratories
· By Distribution Channel
o Hospital Pharmacy
o Retail Pharmacy
o Online Pharmacy
· By Region
o North America
o South America
o Europe
o Asia-Pacific
o Middle East & Africa
Key Players Landscape and Outlook
Key participants in the brain cancer market include F. Hoffmann-La Roche Ltd., Bayer AG, Bristol-Myers Squibb Company, EpicentRx, Inc., and Siemens Healthineer. The market is expected to witness significant growth owing to rising investments by major market players in research and development activities and strategic collaborations. In 2023, the partnership between Ever Fortune and medical equipment giants Siemens Healthineers and General Electric Company (GE) was announced. Following the collaboration with the medical equipment giants, Ever Fortune is expected to focus on its expansion in the Southeast Asian market and strengthen its cooperation with major companies.
Key Players Operating in Global Brain Cancer Market are:
· Pfizer, Inc.
· F. Hoffmann-La Roche Ltd.
· Bayer AG
· Bristol-Myers Squibb Company
· Novartis AG
· Johnson & Johnson Inc.
· Dr. Reddy's Laboratories Ltd.
· Amgen Inc.
· EpicentRx, Inc.
· Siemens Healthineer
Markets and Data’s report answers the following questions:
· What is the current and future market size of the product/service in question globally or specific to different countries?
· How are the markets divided into different product/service segments and the market size and growth of each segment?
· What is the market potential of different product segments and their investment case?
· How are the markets predicted to develop in the future and what factors will drive or inhibit growth?
· What is the business environment and regulatory landscape specific to the product/service?
If you can't find what you're searching for or have any custom requirements for global brain cancer market, you may approach our team at info@marketsandata.com
Table of Contents
1. Research Methodology
2. Project Scope & Definitions
3. Executive Summary
4. Global Brain Cancer Market Outlook, 2017-2031F
4.1. Market Size & Forecast
4.1.1.By Value
4.1.2.By Volume
4.2.1.Carmustine
4.2.2.Cisplatin
4.2.3.Bevacizumab
4.2.4.Temozolomide
4.2.5.Belzutifan
4.2.6.Others
4.3. By Therapy
4.3.1.Chemotherapy
4.3.2.Targeted Therapy
4.3.3.Immunotherapy
4.3.4.Others
4.4. By Indication
4.4.1.Pituitary
4.4.2.Glioma
4.4.3.Meningioma
4.4.4.Others
4.5. By End-user
4.5.1.Hospitals
4.5.2.Cancer Centers
4.5.3.Diagnostic Laboratories
4.6. By Distribution Channel
4.6.1.Hospital Pharmacy
4.6.2.Retail Pharmacy
4.6.3.Online Pharmacy
4.7. By Region
4.7.1.North America
4.7.2.South America
4.7.3.Europe
4.7.4.Asia-Pacific
4.7.5.Middle East & Africa
4.8. By Company Market Share (%), 2023
5. Global Brain Cancer Market Outlook, By Region, 2017-2031F
5.1. North America*
5.1.1.Market Size & Forecast
5.1.1.1. By Value
5.1.1.2. By Volume
5.1.2.By Drug
5.1.2.1. Carmustine
5.1.2.2. Cisplatin
5.1.2.3. Bevacizumab
5.1.2.4. Temozolomide
5.1.2.5. Belzutifan
5.1.2.6. Others
5.1.3.By Therapy
5.1.3.1. Chemotherapy
5.1.3.2. Targeted Therapy
5.1.3.3. Immunotherapy
5.1.3.4. Others
5.1.4.By Indication
5.1.4.1. Pituitary
5.1.4.2. Glioma
5.1.4.3. Meningioma
5.1.4.4. Others
5.1.5.By End-user
5.1.5.1. Hospitals
5.1.5.2. Cancer Centers
5.1.5.3. Diagnostic Laboratories
5.1.6.By Distribution Channel
5.1.6.1. Hospital Pharmacy
5.1.6.2. Retail Pharmacy
5.1.6.3. Online Pharmacy
5.1.7.United States*
5.1.7.1. Market Size & Forecast
5.1.7.1.1. By Value
5.1.7.1.2. By Volume
5.1.7.2. By Drug
5.1.7.2.1. Carmustine
5.1.7.2.2. Cisplatin
5.1.7.2.3. Bevacizumab
5.1.7.2.4. Temozolomide
5.1.7.2.5. Belzutifan
5.1.7.2.6. Others
5.1.7.3. By Therapy
5.1.7.3.1. Chemotherapy
5.1.7.3.2. Targeted Therapy
5.1.7.3.3. Immunotherapy
5.1.7.3.4. Others
5.1.7.4. By Indication
5.1.7.4.1. Pituitary
5.1.7.4.2. Glioma
5.1.7.4.3. Meningioma
5.1.7.4.4. Others
5.1.7.5. By End-user
5.1.7.5.1. Hospitals
5.1.7.5.2. Cancer Centers
5.1.7.5.3. Diagnostic Laboratories
5.1.7.6. By Distribution Channel
5.1.7.6.1. Hospital Pharmacy
5.1.7.6.2. Retail Pharmacy
5.1.7.6.3. Online Pharmacy
5.1.8.Canada
5.1.9.Mexico
*All segments will be provided for all regions and countries covered
5.2. Europe
5.2.1.Germany
5.2.2.France
5.2.3.Italy
5.2.4.United Kingdom
5.2.5.Russia
5.2.6.Netherlands
5.2.7.Spain
5.2.8.Turkey
5.2.9.Poland
5.3. Asia-Pacific
5.3.1.India
5.3.2.China
5.3.3.Japan
5.3.4.Australia
5.3.5.Vietnam
5.3.6.South Korea
5.3.7.Indonesia
5.3.8.Philippines
5.4. South America
5.4.1.Brazil
5.4.2.Argentina
5.5. Middle East & Africa
5.5.1.Saudi Arabia
5.5.2.UAE
5.5.3.South Africa
6. Market Mapping, 2023
6.1. By Drug
6.2. By Therapy
6.3. By Indication
6.4. By End-user
6.5. By Distribution Channel
6.6. By Region
7. Macro Environment and Industry Structure
7.1. Supply Demand Analysis
7.2. Import Export Analysis
7.3. Value Chain Analysis
7.4. PESTEL Analysis
7.4.1. Political Factors
7.4.2. Economic System
7.4.3. Social Implications
7.4.4. Technological Advancements
7.4.5. Environmental Impacts
7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5. Porter’s Five Forces Analysis
7.5.1. Supplier Power
7.5.2. Buyer Power
7.5.3. Substitution Threat
7.5.4. Threat from New Entrant
7.5.5. Competitive Rivalry
8. Market Dynamics
8.1. Growth Drivers
8.2. Growth Inhibitors (Challenges and Restraints)
9. Regulatory Framework and Innovation
9.1. Patent Landscape
9.2. Regulatory Approvals
9.3. Innovations/Emerging Technologies
10. Key Players Landscape
10.1. Competition Matrix of Top Five Market Leaders
10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4. SWOT Analysis (For Five Market Players)
10.5. Patent Analysis (If Applicable)
11. Pricing Analysis
12. Case Studies
13. Key Players Outlook
13.1. Pfizer, Inc.
13.1.1. Company Details
13.1.2. Key Management Personnel
13.1.3. Products & Services
13.1.4. Financials (As reported)
13.1.5. Key Market Focus & Geographical Presence
13.1.6. Recent Developments
13.2. F. Hoffmann-La Roche Ltd.
13.3. Bayer AG
13.4. Bristol-Myers Squibb Company
13.5. Novartis AG
13.6. Johnson & Johnson Inc.
13.7. Dr. Reddy's Laboratories Ltd.
13.8. Amgen Inc.
13.9. EpicentRx, Inc.
13.10. Siemens Healthineer
*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work
14. Strategic Recommendations
15. About Us & Disclaimer
List of Figures
Figure 1. Global Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 2. Global Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 3. Global Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 4. Global Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 5. Global Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 6. Global Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 7. Global Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 8. Global Brain Cancer Market Share (%), By Region, 2017-2031F
Figure 9. North America Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 10. North America Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 11. North America Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 12. North America Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 13. North America Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 14. North America Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 15. North America Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 16. North America Brain Cancer Market Share (%), By Country, 2017-2031F
Figure 17. United States Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 18. United States Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 19. United States Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 20. United States Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 21. United States Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 22. United States Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 23. United States Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 24. Canada Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 25. Canada Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 26. Canada Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 27. Canada Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 28. Canada Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 29. Canada Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 30. Canada Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 31. Mexico Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 32. Mexico Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 33. Mexico Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 34. Mexico Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 35. Mexico Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 36. Mexico Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 37. Mexico Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 38. Europe Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 39. Europe Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 40. Europe Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 41. Europe Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 42. Europe Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 43. Europe Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 44. Europe Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 45. Europe Brain Cancer Market Share (%), By Country, 2017-2031F
Figure 46. Germany Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 47. Germany Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 48. Germany Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 49. Germany Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 50. Germany Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 51. Germany Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 52. Germany Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 53. France Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 54. France Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 55. France Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 56. France Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 57. France Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 58. France Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 59. France Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 60. Italy Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 61. Italy Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 62. Italy Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 63. Italy Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 64. Italy Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 65. Italy Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 66. Italy Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 67. United Kingdom Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 68. United Kingdom Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 69. United Kingdom Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 70. United Kingdom Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 71. United Kingdom Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 72. United Kingdom Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 73. United Kingdom Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 74. Russia Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 75. Russia Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 76. Russia Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 77. Russia Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 78. Russia Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 79. Russia Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 80. Russia Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 81. Netherlands Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 82. Netherlands Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 83. Netherlands Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 84. Netherlands Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 85. Netherlands Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 86. Netherlands Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 87. Netherlands Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 88. Spain Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 89. Spain Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 90. Spain Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 91. Spain Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 92. Spain Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 93. Spain Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 94. Spain Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 95. Turkey Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 96. Turkey Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 97. Turkey Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 98. Turkey Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 99. Turkey Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 100. Turkey Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 101. Turkey Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 102. Poland Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 103. Poland Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 104. Poland Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 105. Poland Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 106. Poland Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 107. Poland Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 108. Poland Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 109. South America Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 110. South America Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 111. South America Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 112. South America Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 113. South America Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 114. South America Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 115. South America Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 116. South America Brain Cancer Market Share (%), By Country, 2017-2031F
Figure 117. Brazil Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 118. Brazil Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 119. Brazil Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 120. Brazil Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 121. Brazil Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 122. Brazil Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 123. Brazil Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 124. Argentina Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 125. Argentina Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 126. Argentina Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 127. Argentina Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 128. Argentina Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 129. Argentina Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 130. Argentina Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 131. Asia-Pacific Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 132. Asia-Pacific Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 133. Asia-Pacific Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 134. Asia-Pacific Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 135. Asia-Pacific Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 136. Asia-Pacific Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 137. Asia- Pacific Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 138. Asia-Pacific Brain Cancer Market Share (%), By Country, 2017-2031F
Figure 139. India Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 140. India Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 141. India Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 142. India Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 143. India Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 144. India Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 145. India Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 146. China Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 147. China Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 148. China Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 149. China Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 150. China Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 151. China Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 152. China Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 153. Japan Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 154. Japan Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 155. Japan Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 156. Japan Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 157. Japan Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 158. Japan Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 159. Japan Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 160. Australia Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 161. Australia Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 162. Australia Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 163. Australia Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 164. Australia Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 165. Australia Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 166. Australia Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 167. Vietnam Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 168. Vietnam Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 169. Vietnam Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 170. Vietnam Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 171. Vietnam Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 172. Vietnam Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 173. Vietnam Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 174. South Korea Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 175. South Korea Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 176. South Korea Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 177. South Korea Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 178. South Korea Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 179. South Korea Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 180. South Korea Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 181. Indonesia Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 182. Indonesia Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 183. Indonesia Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 184. Indonesia Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 185. Indonesia Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 186. Indonesia Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 187. Indonesia Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 188. Philippines Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 189. Philippines Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 190. Philippines Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 191. Philippines Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 192. Philippines Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 193. Philippines Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 194. Philippines Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 195. Middle East & Africa Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 196. Middle East & Africa Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 197. Middle East & Africa Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 198. Middle East & Africa Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 199. Middle East & Africa Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 200. Middle East & Africa Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 201. Middle East & Africa Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 202. Middle East & Africa Brain Cancer Market Share (%), By Country, 2017-2031F
Figure 203. Saudi Arabia Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 204. Saudi Arabia Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 205. Saudi Arabia Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 206. Saudi Arabia Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 207. Saudi Arabia Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 208. Saudi Arabia Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 209. Saudi Arabia Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 210. UAE Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 211. UAE Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 212. UAE Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 213. UAE Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 214. UAE Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 215. UAE Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 216. UAE Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 217. South Africa Brain Cancer Market, By Value, In USD Billion, 2017-2031F
Figure 218. South Africa Brain Cancer Market, By Volume, In Million Units, 2017-2031F
Figure 219. South Africa Brain Cancer Market Share (%), By Drug, 2017-2031F
Figure 220. South Africa Brain Cancer Market Share (%), By Therapy, 2017-2031F
Figure 221. South Africa Brain Cancer Market Share (%), By Indication, 2017-2031F
Figure 222. South Africa Brain Cancer Market Share (%), By End-user, 2017-2031F
Figure 223. South Africa Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
Figure 224. By Drug Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 225. By Therapy Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 226. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 227. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 228. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 229. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
List of Tables
Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects
Frequently Asked Questions
Who are the key players operating in global brain cancer market?
What regions are covered in the final report of brain cancer market?
What are the major factors influencing the growth of global brain cancer market?
What is the market size and growth rate of global brain cancer market?
See Related Reports
Global Bump Stopper Market Assessment Opportunities and Forecast, 2017-2031F
Global bump stopper market is projected to witness a CAGR of 6.54% during the forecast period 2024-2031, growing from USD 27.12 billion in 2023 to USD 45.02 billion in 2031. ....Read More
Published on
April 2024
4,500
Global Exhaust Hanger Market Assessment Opportunities and Forecast, 2017-2031F
Global exhaust hanger market is estimated to witness a CAGR of 5.54% during the forecast period 2024-2031, rising from USD 40.2 billion in 2023 to USD 61.88 billion in 2031. ....Read More
Published on
April 2024
4,500
Global Stabilizer Bar Bushing Market Assessment Opportunities and Forecast, 2017-2031F
Global stabilizer bar bushing market is anticipated to witness a CAGR of 8.64% in the forecast period 2024-2031, rising from USD 12.5 billion in 2023 to USD 24.26 billion in 2031.....Read More
Published on
April 2024
4,500
Global Torque Rod / Strut Market Assessment Opportunities and Forecast, 2017-2031F
Global torque rod/strut market is projected to witness a CAGR of 5.84% during the forecast period 2024-2031, growing from USD 21.21 billion in 2023 to USD 33.4 billion in 2031. ....Read More
Published on
April 2024
4,500
Purchase Options
USD ($)
i
3,000
i
4,500
i
5,700
i
8,200
Tired of Searching?
Looking for Customization?
Some other doubt?
Need insights from a cohort?
REACH US
